II. Mechanism
- Monoclonal antibodies (PCSK9 Inhibitor)
III. Indications
- Severe familial Hypercholesterolemia (e.g. LDL Cholesterol >190 mg/dl)
IV. Background
- Available in U.S. as of 2015
V. Preparations
- Praluent (Alirocumab)
- Repatha (Evolocumab)
VI. Efficacy
- See disadvantages below
- Lower LDL Cholesterol up to 60%
- Repatha added to Statin for 2 years prevents one more CV event per 74 treated ($2,000,000 per CV event prevented)
VII. Disadvantages
- Very expensive agents ($14,000 per year)
- New, with only short-term data
- Unknown longterm safety
- Unknown mortality reduction (contrast with proven Statin efficacy)
VIII. References
- (2015) Presc Lett 22(9): 50-1
- Robinson (2015) N Engl J Med 372(16):1489-99 +PMID:25773378 [PubMed]
- Stroes (2014) J Am Coll Cardiol 63(23):2541-8 [PubMed]
Images: Related links to external sites (from Bing)
Related Studies
| praluent (on 10/19/2016 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| PRALUENT 150 MG/ML PEN | $531.64 per ml | |
| PRALUENT 75 MG/ML PEN | $540.44 per ml | |
| repatha (on 3/22/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| REPATHA 140 MG/ML SURECLICK | $540.38 per ml | |
